triazolam has been researched along with Respiratory Insufficiency in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Respiratory Insufficiency: Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sullivan, RJ | 1 |
1 other study available for triazolam and Respiratory Insufficiency
| Article | Year |
|---|---|
Respiratory depression requiring ventilatory support following 0.5 mg of triazolam.
Topics: Aged; Aged, 80 and over; Female; Humans; Respiration, Artificial; Respiratory Insufficiency; Triazol | 1989 |